The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction

Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease

(2011) Pamela E. Potter et al.   ACTA NEUROPATHOLOGICA

Fully automated synthesis of the M1 receptor agonist [11C]GSK1034702 for clinical use on an Eckert & Ziegler Modular Lab system

(2011) Mickael Huiban et al.   APPLIED RADIATION AND ISOTOPES

Sensitivity and Test-Retest Reliability of the International Shopping List Test in Assessing Verbal Learning and Memory in Mild Alzheimer's Disease

(2011) T. A. C. Thompson et al.   ARCHIVES OF CLINICAL NEUROPSYCHOLOGY

Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist

(2011) M. L. Watt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease

(2010) Cassia R. Overk et al.   JOURNAL OF CHEMICAL NEUROANATOMY

Facilitation of Long-Term Potentiation by Muscarinic M1 Receptors Is Mediated by Inhibition of SK Channels

(2010) Katherine A. Buchanan et al.   NEURON

Modes and Models of Forebrain Cholinergic Neuromodulation of Cognition

(2010) Michael E Hasselmo et al.   NEUROPSYCHOPHARMACOLOGY

Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists

(2010) Brian Budzik et al.   ACS Medicinal Chemistry Letters

AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model

(2009) Stefania Risso Bradley et al.   NEUROPHARMACOLOGY

Synergistic effects of genetic variation in nicotinic and muscarinic receptors on visual attention but not working memory

(2009) P. M. Greenwood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M₁ receptor agonist, AC-260584.

(2008) Kimberly E. Vanover et al.   BEHAVIORAL NEUROSCIENCE

The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine

(2008) Amy Fredrickson et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Cholinergic-Mediated IP3-Receptor Activation Induces Long-Lasting Synaptic Enhancement in CA1 Pyramidal Neurons

(2008) D. F. de Sevilla et al.   JOURNAL OF NEUROSCIENCE

Pharmacological Assessment of M1 Muscarinic Acetylcholine Receptor-Gq/11 Protein Coupling in Membranes Prepared from Postmortem Human Brain Tissue

(2008) H. Salah-Uddin et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS